Defining the Role of Basal and Prandial Insulin for Optimal Glycemic Control

Journal of the American College of Cardiology

Volumn 53, Issue 5 SUPPL., 2009, Pages

  Horton, Edward S ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

diabetes; hemoglobin A1C; hyperglycemia; insulin

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACARBOSE; ALPHA GLUCOSIDASE INHIBITOR; ANTIDIABETIC AGENT; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLIBENCLAMIDE; GLICLAZIDE; GLIMEPIRIDE; GLIPIZIDE; GLUCAGON LIKE PEPTIDE 1 MIMETIC; GLUCOSE; HEMOGLOBIN A1C; HUMAN INSULIN; INSULIN; INSULIN ASPART; INSULIN DETEMIR; INSULIN GLARGINE; INSULIN GLULISINE; INSULIN LISPRO; ISOPHANE INSULIN; METFORMIN; MIGLITOL; NATEGLINIDE; PIOGLITAZONE; PRAMLINTIDE; REPAGLINIDE; ROSIGLITAZONE; SITAGLIPTIN; SULFONYLUREA; UNCLASSIFIED DRUG; UNINDEXED DRUG;

CARDIOVASCULAR RISK; CELL FUNCTION; CLINICAL TRIAL; DRUG ABSORPTION; DRUG DOSE TITRATION; DRUG EFFICACY; FLUID RETENTION; GASTROINTESTINAL SYMPTOM; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEART FAILURE; HEART INFARCTION; HUMAN; HYPERGLYCEMIA; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET CELL; PRIORITY JOURNAL; RETINOPATHY; REVIEW; SIDE EFFECT; STOMACH EMPTYING; STROKE; TREATMENT OUTCOME; WEIGHT GAIN; WEIGHT REDUCTION;

BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN-SECRETING CELLS; RISK FACTORS;

EID: 58549103962     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2008.11.008     Document Type: Review

References (31)

1. Kahn S.E. The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of type 2 diabetes. Diabetologia 46 (2003) 3-19
2. Butler A.E., Janson J., Bonner-Weir S., et al. Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes 52 (2003) 102-110
3. Steppel J.H., and Horton E.S. Beta-cell failure in the pathogenesis of type 2 diabetes mellitus. Curr Diabetes Rep 4 (2004) 169-175
4. Nathan D.M., Buse J.B., Davidson M.B., et al. Management of hyperglycemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy. Update regarding the thiazolidinediones. Diabetologia 51 (2008) 8-11
5. Ford E.S., Li C., Little R.R., and Mokdad A.H. Trends in A1C concentrations among U.S. adults with diagnosed diabetes from 1999 to 2004. Diabetes Care 31 (2008) 102-104
6. Stratton I.M., Adlae A.I., Neil H.A., et al. Association of glycemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 321 (2000) 405-412
7. Kuusisto J., Mykkänen L., Pyörälä K., and Laakso M. NIDDM and its metabolic control predict coronary heart disease in elderly subjects. Diabetes 43 (1994) 960-967
8. Klein R. Hyperglycemia and microvascular and macrovascular disease in diabetes. Diabetes Care 18 (1995) 258-268
9. Standl E., Balletshofer B., Dahl B., et al. Predictors of 10-year macrovascular and overall mortality in patients with NIDDM: the Munich General Practitioner Project. Diabetologia 39 (1996) 1540-1545
10. Middelbeek R.J., and Horton E.S. The role of glucose as an independent cardiovascular risk factor. Curr Diabetes Rep 7 (2007) 43-49
11. The DECODE Study Group. Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. Lancet 354 (1999) 617-621
12. Donahue R.P., Abbott R.D., Reed D.M., and Yano K. Postchallenge glucose concentration and coronary heart disease in men of Japanese ancestry. Honolulu Heart Program. Diabetes 36 (1987) 689-692
13. Qiao Q., Tuomilehto J., and Borch-Johnsen K. Post-challenge hyperglycemia is associated with premature death and macrovascular complications. Diabetologia 46 Suppl 1 (2003) M17-M21
14. Hanefeld M., Fischer S., Julius U., et al. Risk factors for myocardial infarction and death in newly detected NIDDM: the Diabetes Intervention Study, 11-year follow-up. Diabetologia 39 (1996) 1577-1583
15. de Vegt F., Dekker J.M., Ruhé H.G., et al. Hyperglycemia is associated with all-cause and cardiovascular mortality in the Hoorn population: the Hoorn Study. Diabetologia 42 (1999) 926-931
16. Cavalot F., Petrelli A., Traversa M., et al. Postprandial blood glucose is a stronger predictor of cardiovascular events than fasting blood glucose in type 2 diabetes mellitus, particularly in women: lessons from the San Luigi Gonzaga Diabetes Study. J Clin Endocrinol Metab 91 (2006) 813-819
17. The Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 358 (2008) 2545-2559
18. The ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 358 (2008) 2560-2572
19. American Diabetes Association. Standards of medical care in diabetes-2008. Diabetes Care 31 Suppl 1 (2008) S12-S54
20. Abraira C., Duckworth W.C., and VADT Investigators. Glycemic control and cardiovascular outcomes-the VA trial (2008) Paper presented at: 68th Annual Scientific Sessions of the American Diabetes Association; June 8, San Francisco, CA.
21. Nauk M.A., Meininger G., Sheng D., Terranella L., Stein P.P., and Sitagliptin Study 024 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial. Diabetes Obes Metab 9 (2007) 194-205
22. Nesto R.W., Bell D., Bonow R.O., et al., American Heart Association; American Diabetes Association. Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and the American Diabetes Association. Circulation 108 (2003) 2941-2948
23. Nissen S.E., and Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 356 (2007) 2457-2471
24. Lincoff A.M., Wolski K., Nicholls S.J., and Nissen S.E. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes: a meta-analysis of randomized trials. JAMA 298 (2007) 1180-1188
25. Home P.D., Pocock S.J., Beck-Nielsen H., et al., RECORD Study Group. Rosiglitazone evaluated for cardiovascular outcomes-an interim analysis. N Engl J Med 357 (2007) 28-8
26. Kahn S.E., Haffner S.M., Heise M.A., et al., ADOPT Study Group. Glycemic durability of rosiglitazone, metformin or glyburide monotherapy. N Engl J Med 355 (2006) 2427-2443
27. Nissen S.E., Nicholls S.J., Wolski K., et al., PERISCOPE Investigators. Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial. JAMA 299 (2008) 1561-1573
28. Denker P.S., and Dimarco P.E. Exenatide (exendin-4)-induced pancreatitis: a case report. Diabetes Care 29 (2006) 471
29. Ahmad S.R., and Swann J. Exenatide and rare adverse events. N Engl J Med 358 (2008) 1970-1971
30. Mooradian A.D., Bernbaum M., and Albert S.G. Narrative review: a rational approach to starting insulin therapy. Ann Intern Med 145 (2006) 125-134
31. Rosenstock J., Ahmann A.J., Colon G., et al. Advancing insulin therapy in type 2 diabetes previously treated with glargine plus oral agents: prandial premixed (insulin lispro protamine suspension/lispro) versus basal/bolus (glargine/lispro) therapy. Diabetes Care 31 (2008) 20-25